Ring Vaccination with rVSV-ZEBOV Under Expanded Access in Response to an Outbreak of Ebola Virus Disease in Guinea 2016 An Operational and Vaccine S
Gsell, P., Camacho, A., Kucharski, A., et al. (2017). Ring Vaccination with rVSV-ZEBOV Under Expanded Access in Response to an Outbreak of Ebola Virus Disease in Guinea, 2016: An Operational and Vaccine Safety Report. The Lancet. 17(12):1276-84.
The authors describe the first use of an Ebola vaccine in an outbreak setting outside of a clinical trial. More than 1500 individuals, including 303 children age 6 and older, were vaccinated in 4 rings. No confirmed cases were reported among vaccinees or within the rings once vaccination was completed. Mild adverse events were reported in 17% of those age 6-17; 36% of adults also reported adverse events, with 98% being mild. There were no reports of severe vaccine-related adverse events.